Adquey

Adquey is used to treat mild to moderate atopic dermatitis (eczema) in adults and children 2 years and older. It is a topical ointment applied twice daily.

Adquey (difamilast) gained FDA approval on February 12, 2026.

The most common side effect of Adquey is nasopharyngitis (also known as a common cold).

Less common side effects affecting less than 1% of people using Adquey are:

• Infected hair follicles at the application site folliculitis)
• Contact dermatitis
• Application site rash
• Molluscum contagiosum (a viral skin infection that causes small raised bumps).

To report suspected side effects, contact Acrotech Biopharma Inc., at 1-888-292-9617 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Across three clinical trials involving adults and children aged 2 and older with mild to moderate atopic dermatitis, Adquey consistently outperformed the vehicle (inactive comparator) after just four weeks of treatment.

• In the multinational trial, 21% of Adquey users achieved treatment success compared to just 3% in the vehicle group.
• Results were even stronger in the two Japanese trials, where 38% and 47% of Adquey users, respectively, reached treatment success, compared to 13% and 18% in the vehicle groups. Treatment success was defined as clear or nearly clear skin with a significant improvement from the starting point.

Adquey (difamilast) works by blocking an enzyme in the body called PDE-4, which is normally responsible for breaking down a chemical messenger inside cells known as cyclic AMP. When PDE-4 is blocked, cyclic AMP builds up inside cells, which in turn reduces the production of inflammatory substances called cytokines and chemokines. By dampening this inflammatory response, Adquey relieves the symptoms of dermatitis, although the exact way it works is not fully understood.

Adquey (difamilast) belongs to the drug class called phosphodiesterase 4 inhibitors.

Before applying Adquey, tell your healthcare provider about all your medical conditions, including if you:

• Have had an allergic reaction to Adquey, difamilast, or any of the inactive ingredients in the ointment (see the end of this guide for a list of ingredients)
• Are pregnant or intend to become pregnant
• Are breastfeeding or intend to breastfeed. Do not apply Adquey to the nipple area or areola to reduce the risk of your baby coming into contact with it.

Adquey is for topical use only and not for ophthalmic, oral, or intravaginal use.

Apply a thin layer of Adquey twice daily to the affected areas of skin and rub it in completely.

• Wash your hands after applying.
• Avoid areas of the skin that are infected when applying Adquey.

No clinical drug interaction trials have been conducted with topical Adquey (difamilast).

Store Adquey at room temperature away from direct sunlight, heat, and moisture.

Keep the tube tightly closed.

Keep out of reach of children.

Active ingredient: difamilast 1%

Inactive ingredients: mineral oil, paraffin, propylene carbonate, white petrolatum, and white wax.

Adquey (difamilast) ointment, 1% is a white to off-white ointment supplied in the following packages:

• 27 g tube (NDC 72893-017-08)
• 85 g tube (NDC 72893-017-09)

Adquey is manufactured for Acrotech Biopharma Inc., East Windsor, NJ 08520 USA.